Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-DCFPyL vs 18F-NaF-PET Imaging in Metastatic Prostate Cancer
NCT03173924Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of piflufolastat f 18 in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoint: Accuracy of DCFPyL-PET/CT diagnostics at 36 months. Started Jun 2017; status: active, not recruiting.
02
Drugs
piflufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03173924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03173924.